Tim Osborne
Net worth: 252 132 $ as of 2026-05-30
Net worth: 252 132 $ as of 2026-05-30
Tim Osborne currently works at Forward Air Corp., as Executive Vice President-Operations from 2024.
Dr. Osborne also formerly worked at the University of California, Irvine, as Principal and Select BioVentures LLC, as Advisor.
Dr. Osborne received his undergraduate degree from King University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-14 | 23,831 ( 0.08% ) | 252 132 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| FORWARD AIR CORPORATION | Chief Operating Officer | 2023-12-31 |
| Companies | Position | End |
|---|---|---|
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Private Equity Investor | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Forward Air Corp.
Forward Air Corp. TruckingTransportation Provides less-than-truckload, final mile, truckload and intermodal drayage services | Transportation |
King University
King University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Finance |
Select your edition
All financial news and data tailored to specific country editions